A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors

Basal aurora kinase B activity is sufficient for histone H3 phosphorylation in prophase

(2013) L.-T.-T. Le et al.   Biology Open

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

(2012) Y Lin et al.   BRITISH JOURNAL OF CANCER

The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas

(2012) Vikas Sehdev et al.   CANCER

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

(2012) E. C. Dees et al.   CLINICAL CANCER RESEARCH

Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase

(2011) Alexander Pflug et al.   BIOCHEMICAL JOURNAL

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

(2011) Wenqing Qi et al.   BIOCHEMICAL PHARMACOLOGY

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

(2010) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

(2010) T. Shimomura et al.   MOLECULAR CANCER THERAPEUTICS

Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor

(2009) Teresa Sardon et al.   CHEMBIOCHEM

Novel targets in esophageal and gastric cancer: beyond antiangiogenesis

(2009) Wooin Lee et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

(2009) Christopher D Scharer et al.   Journal of Translational Medicine

Aurora kinases as targets for cancer therapy

(2007) Giannis Mountzios et al.   CANCER TREATMENT REVIEWS